Literature DB >> 25142050

Anticholinergic medications: an additional contributor to cognitive impairment in the heart failure population?

Arslan Shaukat1, Amir Habib, Kathleen A Lane, Changyu Shen, Saba Khan, Yaron M Hellman, Malaz Boustani, Adnan S Malik.   

Abstract

BACKGROUND/
OBJECTIVES: Patients with congestive heart failure (CHF) have a high prevalence of cognitive impairment and the association is multifactorial. In general, the burden of anticholinergic drugs has consistently been shown to be a risk factor for cognitive impairment in the elderly. The aim of this study was to assess the cognitive burden of medications in patients with CHF.
DESIGN: This was a cross-sectional, retrospective, single-center study.
SETTING: The study was conducted in an outpatient setting. PARTICIPANTS: Patients who presented to a comprehensive heart failure clinic during a 1-month period were included. MEASUREMENTS: The primary outcomes of interest were mean anticholinergic cognitive burden (ACB) score of all medications and CHF medications (ACB-CHF), calculated based on the ACB Scoring Scale (ACB-SS). The ACB-CHF score was further dichotomized as 0 or 1 (low anticholinergic burden) versus 2 or 3 (high anticholinergic burden).
RESULTS: A total of 182 patients were included. The mean ACB and ACB-CHF scores were 2.4 (range 0-13) and 1.0 (range 0-4), respectively, while 25.8 % of patients had an ACB-CHF score of 2 or 3. There was no association found between ejection fraction in patients with systolic heart failure and the ACB (p = 0.28) or ACB-CHF (p = 0.62) score.
CONCLUSION: We conclude that patients with CHF have a substantial exposure to anticholinergic medications with adverse cognitive effects. This may be another important contributor to the increased prevalence of cognitive impairment in these patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25142050     DOI: 10.1007/s40266-014-0204-2

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  20 in total

1.  Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: A prospective study.

Authors:  Juho Uusvaara; Kaisu H Pitkala; Hannu Kautiainen; Reijo S Tilvis; Timo E Strandberg
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

2.  Executive dysfunction and depressive symptoms associated with reduced participation of people with severe congestive heart failure.

Authors:  Erin R Foster; Kathleen B Cunnane; Dorothy F Edwards; M Tracy Morrison; Gregory A Ewald; Edward M Geltman; Allyson R Zazulia
Journal:  Am J Occup Ther       Date:  2011 May-Jun

Review 3.  Neuropsychiatric effects of cardiovascular drug therapy.

Authors:  Seth Keller; William H Frishman
Journal:  Cardiol Rev       Date:  2003 Mar-Apr       Impact factor: 2.644

4.  Cognitive function in patients with decompensated heart failure: the Cognitive Impairment in Heart Failure (CogImpair-HF) study.

Authors:  Ingrid Kindermann; Denise Fischer; Julia Karbach; Andreas Link; Katrin Walenta; Christine Barth; Christian Ukena; Felix Mahfoud; Volker Köllner; Michael Kindermann; Michael Böhm
Journal:  Eur J Heart Fail       Date:  2012-04       Impact factor: 15.534

Review 5.  Cognitive impairment in heart failure: a systematic review of the literature.

Authors:  Raymond L C Vogels; Philip Scheltens; Jutta M Schroeder-Tanka; Henry C Weinstein
Journal:  Eur J Heart Fail       Date:  2006-12-14       Impact factor: 15.534

6.  Association of anticholinergic activity of prescribed medications with postoperative delirium.

Authors:  L Tune; S Carr; T Cooper; B Klug; R C Golinger
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1993       Impact factor: 2.198

7.  Cardiac dysfunction and cognition in older adults with heart failure.

Authors:  Karin F Hoth; Athena Poppas; David J Moser; Robert H Paul; Ronald A Cohen
Journal:  Cogn Behav Neurol       Date:  2008-06       Impact factor: 1.600

8.  Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study.

Authors:  Iacopo Cancelli; Gian Luigi Gigli; Antonella Piani; Barbara Zanchettin; Francesco Janes; Adriana Rinaldi; Mariarosaria Valente
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

Review 9.  The cognitive impact of anticholinergics: a clinical review.

Authors:  Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

Review 10.  Heart failure and cognitive impairment: challenges and opportunities.

Authors:  George A Heckman; Christopher J Patterson; Catherine Demers; Joye St Onge; Irene D Turpie; Robert S McKelvie
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more
  3 in total

1.  Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden.

Authors:  Ariel R Green; Liza M Reifler; Cynthia M Boyd; Linda A Weffald; Elizabeth A Bayliss
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

2.  Polypharmacy among older adults with dementia compared with those without dementia in the United States.

Authors:  Matthew E Growdon; Siqi Gan; Kristine Yaffe; Michael A Steinman
Journal:  J Am Geriatr Soc       Date:  2021-06-08       Impact factor: 7.538

3.  A prospective cohort study investigating contributors to mild cognitive impairment in adults with spinal cord injury: study protocol.

Authors:  Danielle Sandalic; Ashley Craig; Mohit Arora; Ilaria Pozzato; Grahame Simpson; Bamini Gopinath; Jasbeer Kaur; Sachin Shetty; Gerard Weber; Ian Cameron; Yvonne Tran; James Middleton
Journal:  BMC Neurol       Date:  2020-09-11       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.